Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February

OSLO, Norway, Feb. 9, 2023 /PRNewswire/ -- Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, will release its fourth quarter and second half 2022 results on Thursday, 16 February 2023 at 8am CEST. The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 2:30pm CEST.

We encourage you to send us questions in advance, to be addressed during the Q&A session. Please send your email to [email protected].

The presentation and subsequent Q&A session will be held in English and may be viewed live by registering here:  https://forms.office.com/e/q06xRZSrBV

A recording of the presentation will be made available on https://www.lytixbiopharma.com/investors/overview.html after the presentation

For more information, please contact:

Gjest Breistein,
CFO
[email protected]

Ole Peter Nordby,
Head of IR & Communication Manager
[email protected]

SOURCE Lytix Biopharma AS

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED